{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:27:52Z","timestamp":1791912472047,"version":"4.3.4"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T00:00:00Z","timestamp":1705881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Myasthenic crisis, a life-threatening exacerbation of myasthenia gravis, is a significant clinical challenge, particularly when refractory to standard therapies. Here, we described a case of myasthenic crisis in which the patient transitioned from refractory myasthenic crisis to minimal symptom expression after receiving add-on treatment with efgartigimod, a novel neonatal Fc receptor antagonist. A 54\u2009years-old woman who was diagnosed with anti-acetylcholine receptor antibody-positive myasthenia gravis experienced respiratory failure necessitating mechanical ventilation. Despite aggressive treatment with plasmapheresis, intravenous immunoglobulins, and high-dose corticosteroids, her condition continued to deteriorate, culminating in persistent myasthenic crisis. Efgartigimod was administered as salvage therapy. Remarkable improvement in neuromuscular function was observed within days, allowing for successful weaning from mechanical ventilation. Over the subsequent weeks, the patient\u2019s symptoms continued to ameliorate, ultimately reaching a state of minimal symptom expression. Serial assessments of her serum anti-acetylcholine receptor antibody titer showed a consistent decline in parallel with this clinical improvement. This case highlights efgartigimod\u2019s potential as an effective therapeutic option for refractory myasthenic crisis, offering new hope for patients facing this life-threatening condition.<\/jats:p>","DOI":"10.3389\/fneur.2024.1321058","type":"journal-article","created":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T04:27:03Z","timestamp":1705897623000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":37,"title":["Case report: Recovery from refractory myasthenic crisis to minimal symptom expression after add-on treatment with efgartigimod"],"prefix":"10.3389","volume":"15","author":[{"given":"Keiko","family":"Watanabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kakinuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuta","family":"Kinno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,22]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/mus.27832","article-title":"Myasthenic crisis","volume":"68","author":"Claytor","year":"2023","journal-title":"Muscle Nerve"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"e299","DOI":"10.1212\/WNL.0000000000008688","article-title":"Myasthenic crisis demanding mechanical ventilation: a multicenter analysis of 250 cases","volume":"94","author":"Neumann","year":"2020","journal-title":"Neurology"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s13311-022-01181-3","article-title":"Antibody therapies in autoimmune neuromuscular junction disorders: approach to myasthenic crisis and chronic management","volume":"19","author":"Vanoli","year":"2022","journal-title":"Neurotherapeutics"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/cen3.12739","article-title":"The Japanese clinical guidelines 2022 for myasthenia gravis and Lambert\u2013Eaton myasthenic syndrome","volume":"14","author":"Murai","year":"2023","journal-title":"Clin Exp Neuroimmunol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/ana.410410615","article-title":"Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group","volume":"41","author":"Gajdos","year":"1997","journal-title":"Ann Neurol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.nurt.2008.08.011","article-title":"Current and future standards in treatment of myasthenia gravis","volume":"5","author":"Gold","year":"2008","journal-title":"Neurotherapeutics"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1196\/annals.1405.038","article-title":"IVIG treatment for myasthenia gravis: effectiveness, limitations, and novel therapeutic strategies","volume":"1132","author":"Zinman","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1229112","DOI":"10.3389\/fneur.2023.1229112","article-title":"FcRN receptor antagonists in the management of myasthenia gravis","volume":"14","author":"Bhandari","year":"2023","journal-title":"Front Neurol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"150767","DOI":"10.1016\/j.tmrv.2023.150767","article-title":"Therapeutic plasma exchange versus FcRn inhibition in autoimmune disease","volume":"38","author":"Mina-Osorio","year":"2023","journal-title":"Transfus Med Rev"},{"key":"ref11","first-page":"82","article-title":"Acetylcholine receptor antibody in myasthenia gravis: predominance of IgG subclasses 1 and 3","volume":"67","author":"R\u00f8dgaard","year":"1987","journal-title":"Clin Exp Immunol"},{"key":"ref12","first-page":"138","article-title":"Intra- and extravascular distribution of albumin and immunoglobulin in man","volume":"11","author":"Rossing","year":"1978","journal-title":"Lymphology"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/mus.27341","article-title":"Myasthenia gravis exacerbation in association with antibody overshoot following plasmapheresis","volume":"64","author":"Ching","year":"2021","journal-title":"Muscle Nerve"},{"key":"ref14","first-page":"457","article-title":"The effect of extracorporeal antibody removal on antibody synthesis and catabolism in immunized rabbits","volume":"60","author":"Charlton","year":"1985","journal-title":"Clin Exp Immunol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"662856","DOI":"10.3389\/fneur.2021.662856","article-title":"Therapeutic plasma exchange in myasthenia gravis: a systematic literature review and meta-analysis of comparative evidence","volume":"12","author":"Ipe","year":"2021","journal-title":"Front Neurol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.clim.2006.09.001","article-title":"Kinetics of FcRn-mediated recycling of IgG and albumin in human: pathophysiology and therapeutic implications using a simplified mechanism-based model","volume":"122","author":"Kim","year":"2007","journal-title":"Clin Immunol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.3389\/fimmu.2019.01540","article-title":"The neonatal Fc receptor (FcRn): a misnomer?","volume":"10","author":"Pyzik","year":"2019","journal-title":"Front Immunol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"3180","DOI":"10.3390\/biomedicines11123180","article-title":"Plasma exchange versus intravenous immunoglobulin in worsening myasthenia gravis: a systematic review and meta-analysis with special attention to faster relapse control","volume":"11","author":"Pavlekovics","year":"2023","journal-title":"Biomedicine"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/s00415-023-11970-1","article-title":"Efgartigimod beyond myasthenia gravis: the role of FcRn-targeting therapies in stiff-person syndrome","volume":"271","author":"Di Stefano","year":"2023","journal-title":"J Neurol"},{"key":"ref20","first-page":"54","article-title":"Stiff-man syndrome","volume-title":"Semin. Neurol.","author":"Toro","year":"1994"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1321058\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T04:27:09Z","timestamp":1705897629000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1321058\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,22]]},"references-count":20,"alternative-id":["10.3389\/fneur.2024.1321058"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2024.1321058","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,22]]},"article-number":"1321058"}}